Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease
Samo za registrovane korisnike
2020
Autori
Miletić Vukajlović, JadrankaDrakulić, Dunja R.
Pejić, Snežana
Ilić, Tihomir V.
Stefanović, Aleksandra
Petković, Marijana
Schiller, Jürgen
Članak u časopisu (Objavljena verzija)
,
© 2019 John Wiley & Sons, Ltd
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters,... in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration. © 2019 John Wiley & Sons, Ltd.
Izvor:
Rapid Communications in Mass Spectrometry, 2020, 34, 4Finansiranje / projekti:
- German Research Foundation (DFG) [SFB 1052/Z3]
- German Research Foundation (DFG) [476/12-2]
- Ćelijska i molekulska osnova neuroinflamacije: potencijala ciljna mesta za translacionu medicinu i terapiju (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41014)
- Bazična i kliničko-farmakološka istraživanja mehanizama dejstva i interakcija lekova u nervnom i kardiovaskularnom sistemu (RS-MESTD-Basic Research (BR or ON)-175023)
DOI: 10.1002/rcm.8595
ISSN: 0951-4198
PubMed: 31519070
WoS: 000508347200007
Scopus: 2-s2.0-85078298349
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Miletić Vukajlović, Jadranka AU - Drakulić, Dunja R. AU - Pejić, Snežana AU - Ilić, Tihomir V. AU - Stefanović, Aleksandra AU - Petković, Marijana AU - Schiller, Jürgen PY - 2020 UR - https://vinar.vin.bg.ac.rs/handle/123456789/8476 AB - Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration. © 2019 John Wiley & Sons, Ltd. T2 - Rapid Communications in Mass Spectrometry T1 - Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease VL - 34 IS - 4 DO - 10.1002/rcm.8595 ER -
@article{ author = "Miletić Vukajlović, Jadranka and Drakulić, Dunja R. and Pejić, Snežana and Ilić, Tihomir V. and Stefanović, Aleksandra and Petković, Marijana and Schiller, Jürgen", year = "2020", abstract = "Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration. © 2019 John Wiley & Sons, Ltd.", journal = "Rapid Communications in Mass Spectrometry", title = "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease", volume = "34", number = "4", doi = "10.1002/rcm.8595" }
Miletić Vukajlović, J., Drakulić, D. R., Pejić, S., Ilić, T. V., Stefanović, A., Petković, M.,& Schiller, J.. (2020). Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry, 34(4). https://doi.org/10.1002/rcm.8595
Miletić Vukajlović J, Drakulić DR, Pejić S, Ilić TV, Stefanović A, Petković M, Schiller J. Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry. 2020;34(4). doi:10.1002/rcm.8595 .
Miletić Vukajlović, Jadranka, Drakulić, Dunja R., Pejić, Snežana, Ilić, Tihomir V., Stefanović, Aleksandra, Petković, Marijana, Schiller, Jürgen, "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease" in Rapid Communications in Mass Spectrometry, 34, no. 4 (2020), https://doi.org/10.1002/rcm.8595 . .